Welcome to our dedicated page for NeuroBo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals stock.
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology company dedicated to developing and commercializing transformative therapies for cardiometabolic diseases. Headquartered in Boston, Massachusetts, and established in 2017, NeuroBo is at the forefront of innovative solutions aimed at conditions like obesity, metabolic dysfunction-associated steatohepatitis (MASH), and Type 2 Diabetes Mellitus (T2DM).
The company's robust product pipeline includes two primary programs:
- DA-1241: This novel G-Protein-Coupled Receptor 119 (GPR119) agonist aims to treat MASH and T2DM. In preclinical studies, DA-1241 has shown promising results in reducing hepatic steatosis, inflammation, liver fibrosis, and improving glucose control. The Phase 2a clinical trial is currently evaluating its efficacy and safety, with an expected data readout in the second half of 2024.
- DA-1726: A dual oxyntomodulin (OXM) analog functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, designed to address obesity. Preclinical evidence suggests that DA-1726 offers superior weight loss and a better tolerability profile compared to existing GLP-1 agonists. The Phase 1 clinical trial is underway with an anticipated data readout in the first half of 2025.
In addition to its primary programs, NeuroBo continues to advance its legacy therapeutics, including ANA001 for viral diseases, NB-01 for painful diabetic neuropathy, NB-02 for neurodegenerative diseases, and Gemcabene for dyslipidemia. The company's commitment to leveraging advanced biotechnology aims to meet significant unmet medical needs, providing patients with novel, effective treatments.
Recent achievements include FDA clearance for the IND application of DA-1726 and the initiation of Phase 1 clinical trials. NeuroBo also secured Institutional Review Board (IRB) approval to further expedite their research and development processes.
For more comprehensive information, please visit NeuroBo Pharmaceuticals' official website.
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. completes enrollment of Part 1 of Phase 2a clinical trial for DA-1241, a GPR119 agonist for MASH treatment. Part 2 to explore combination therapy with sitagliptin. Full trial data expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. received IRB approval for Phase 1 trial of DA-1726 in Obesity and SRC approval for Phase 2a trial of DA-1241 for MASH. The company reported positive pre-clinical safety data for DA-1241 and expects data from Phase 2a trial in the second half of 2024. NeuroBo's cash position was $22.4 million as of December 31, 2023, expected to fund operations into the fourth quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. receives approval to continue Phase 2a clinical trial for DA-1241, a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH). The Safety Review Committee recommends trial continuation without modification after a positive safety review. Full data readout expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.21%
Tags
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. appoints Marshall Woodworth as CFO, highlighting his extensive experience in pharmaceutical and medical device companies. The company aims to leverage Woodworth's expertise in advancing clinical development of cardiometabolic assets, including DA-1241 and DA-1726, targeting metabolic dysfunction-associated steatohepatitis (MASH) and obesity markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) receives IRB approval for Phase 1 trial of DA-1726, a novel cardiometabolic drug targeting obesity. First patient expected to be randomized in Q2 2024. Positive preclinical data suggests potential advantages over existing treatments. Top-line data expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.09%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) announces participation in the BIO CEO & Investor Conference for one-on-one investor meetings and business development discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. has announced the clearance of its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist. Preclinical studies have shown that DA-1726 elicits superior weight loss compared to Semaglutide (Wegovy™) and similar weight loss compared to Tirzepatide (Mounjaro™), while consuming more food. The company plans to initiate a Phase 1 clinical trial for the treatment of obesity in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
67.28%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) announced positive pre-clinical safety data for DA-1241, a GPR119 agonist, in combination with sitagliptin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company has opened enrollment for Part 2 of its Phase 2a clinical trial and expects to report the full data readout in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) has announced that it has regained compliance with Nasdaq's minimum bid price requirement and satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market, resulting in the closing of the listing matter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) announced their participation in the NASH-TAG Conference 2024 and the Biotech Showcase, with their executives virtually attending to engage with clinicians, researchers, investors, and biopharmaceutical executives in the field of cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.23%
Tags
FAQ
What is the current stock price of NeuroBo Pharmaceuticals (NRBO)?
The current stock price of NeuroBo Pharmaceuticals (NRBO) is $2.36 as of November 27, 2024.
What is the market cap of NeuroBo Pharmaceuticals (NRBO)?
The market cap of NeuroBo Pharmaceuticals (NRBO) is approximately 20.3M.
What is NeuroBo Pharmaceuticals, Inc.?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for cardiometabolic diseases.
What are NeuroBo's primary programs?
NeuroBo's primary programs include DA-1241 for the treatment of MASH and T2DM, and DA-1726 for the treatment of obesity.
What is DA-1241?
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist designed to treat MASH and T2DM. It has shown promising preclinical results in reducing liver inflammation and improving glucose control.
What is DA-1726?
DA-1726 is a dual oxyntomodulin (OXM) analog that functions as a GLP1R and GCGR agonist for treating obesity. It has demonstrated superior weight loss in preclinical models.
Where is NeuroBo Pharmaceuticals headquartered?
NeuroBo Pharmaceuticals is headquartered in Boston, Massachusetts.
When was NeuroBo Pharmaceuticals founded?
NeuroBo Pharmaceuticals was founded in 2017.
What recent initiatives has NeuroBo announced?
NeuroBo recently announced FDA clearance for the IND application of DA-1726 and achieved IRB approval to proceed with its Phase 1 clinical trials.
What are NeuroBo's legacy therapeutics?
NeuroBo's legacy therapeutics include ANA001 for viral diseases, NB-01 for painful diabetic neuropathy, NB-02 for neurodegenerative diseases, and Gemcabene for dyslipidemia.
How can I learn more about NeuroBo Pharmaceuticals?
For more information, visit NeuroBo Pharmaceuticals' official website at www.neurobopharma.com.
What is the significance of DA-1726?
DA-1726 could be a groundbreaking treatment for obesity, offering better weight loss and tolerability compared to existing GLP-1 agonists.
NeuroBo Pharmaceuticals, Inc.
Nasdaq:NRBO
NRBO Rankings
NRBO Stock Data
20.33M
3.00M
65.24%
12.71%
0.4%
Biotechnology
Pharmaceutical Preparations
United States of America
CAMBRIDGE